Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03532672 Recruiting - Healthy Clinical Trials

Acute Effect of Fasting

Start date: September 22, 2017
Phase: N/A
Study type: Interventional

The main objective of the study is to evaluate the acute effects of fasting over inflammatory responses.

NCT ID: NCT03531229 Recruiting - Healthy Clinical Trials

Single Ascending Dose Study of Lu AF76432 in Healthy Young Men

Start date: April 17, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate safety, tolerability and pharmacokinetics of the drug Lu AF76432 given as single oral ascending doses to healthy young men

NCT ID: NCT03526120 Recruiting - Healthy Clinical Trials

Pistachio Intake, Satiety and Body Weight Control in Healthy Adult Women

APIS
Start date: February 27, 2018
Phase: N/A
Study type: Interventional

The main goal of the study is to confirm that, due to their rich nutritional content in protein, polyunsaturated fatty acids, vitamins and minerals of interest (calcium and magnesium), the regular consumption of the recommended amount of pistachios by adult women will elicit appropriate satiety and compensation in the daily energy intake, and improve diet quality, anthropometry and body composition.

NCT ID: NCT03525717 Recruiting - Healthy Clinical Trials

Effect of Late Dinner on Nocturnal Metabolism

Start date: May 8, 2018
Phase: N/A
Study type: Interventional

This study examines the impact of routine dinner time versus late dinner time on nocturnal metabolism. Specifically, investigators will examine plasma profiles of free fatty acids, glucose, insulin, triglycerides, and oxidation of dietary fat.

NCT ID: NCT03525405 Recruiting - Healthy Clinical Trials

A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects

Start date: May 2018
Phase: Phase 1
Study type: Interventional

This is a Phase I, single-center, open-label, single-sequence, study evaluating the absorption, metabolism, and excretion of napabucasin in healthy adult male volunteers using a mixture 14C-radiolabeled and unlabeled material.

NCT ID: NCT03524989 Recruiting - Healthy Clinical Trials

The Effect of Hyperbaric Oxygen Therapy on Aerobic and Anaerobic Physical Fitness

SPORTRCT
Start date: May 15, 2018
Phase: N/A
Study type: Interventional

Previous evidence showed hyperbaric oxygen can enhance aerobic and anaerobic performance during the exposure. The effect of continuous exposure of hyperbaric oxygen on performance was never evaluated.

NCT ID: NCT03522220 Recruiting - Healthy Clinical Trials

Augmentation of Neuronal Network Plasticity in Schizophrenia

SCZ
Start date: September 1, 2016
Phase: N/A
Study type: Interventional

Current pathophysiological models of schizophrenia focus on disconnectivity of distributed neuronal systems to explain the multitude of psychic symptoms. However, therapeutic strategies targeting this specific pathobiology are lacking. Our recent work provides strong evidence that complex video-game training interventions facilitate fronto-hippocampal structural and functional connectivity within 2 months in healthy subjects. The planned project transfers this knowledge into a training study in schizophrenic patients to counteract disease-related disconnectivity. Underlying mechanisms and behavioral effects are extensively parametrized by resting state functional magnetic resonance imaging (fMRI), diffusion tensor imaging (DTI), spectroscopy and clinical short- and long-term outcome.

NCT ID: NCT03516487 Recruiting - Healthy Clinical Trials

Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria

PKU
Start date: April 2, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate SYNB1618 (investigational product) in healthy volunteers (HV) and subjects diagnosed with phenylketonuria (PKU) for the possible treatment of PKU. Phenylketonuria (PKU) is a rare inherited metabolic disorder that occurs in people who are missing an enzyme that the body needs to use phenylalanine. Eligible subjects will receive investigational product (IP) in the clinic, and will undergo safety monitoring, evaluations and subsequent follow-up after IP administration.

NCT ID: NCT03516305 Recruiting - Healthy Clinical Trials

Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smokers Versus Non-Smokers

Start date: April 6, 2018
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized, single dose, pharmacokinetic study in 36 healthy adult male and female volunteers, including 18 smokers and 18 non-smokers. All subjects will be administered a single inhaled dose of Staccato alprazolam 1 mg via hand-held inhaler. Blood samples will be drawn for pharmacokinetic analysis. Eligible subjects are admitted to Phase 1 unit for up to 48 hours. Subjects will receive a post-study safety phone call 14 days(± 2 days) after dosing.

NCT ID: NCT03512548 Recruiting - Healthy Clinical Trials

Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites

Start date: April 10, 2018
Phase: Phase 1
Study type: Interventional

This is an open label, single sequence, crossover study. In Part 1, eligible subjects will participate in 3 treatment periods, in which they will receive the following treatments in turn: 1) In Period 1, a single 350 mg dose of relacorilant administered alone, 2) In Period 2, once daily 200 mg doses of itraconazole administered for 3 days; 3) In Period 3, single 350-mg dose of relacorilant administered with a concomitant 200 mg dose of itraconazole and continued once daily 200 mg doses of itraconazole for three additional days. If Part 2 is conducted, eligible subjects will participate in 3 treatment periods, in which they will receive the following treatments in turn: 1) In Period A, 14 days of oral dosing with "higher dose" relacorilant alone; 2) In Period B, 14 days of oral dosing with "lower dose" relacorilant alone; 3) In Period C, 14 days of oral dosing with "lower dose" relacorilant in combination with itraconazole.